Literature DB >> 26392500

Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.

Sunil Parikh1, Fatai Fehintola2, Liusheng Huang3, Alexander Olson3, Waheed A Adedeji4, Kristin M Darin5, Gene D Morse6, Robert L Murphy5, Babafemi O Taiwo5, Olusegun O Akinyinka7, Isaac F Adewole8, Francesca T Aweeka3, Kimberly K Scarsi9.   

Abstract

Coadministration of nevirapine-based antiretroviral therapy (ART) and artemether-lumefantrine is reported to result in variable changes in lumefantrine exposure. We conducted an intensive pharmacokinetic study with 11 HIV-infected adults who were receiving artemether-lumefantrine plus nevirapine-based ART, and we compared the results with those for 16 HIV-negative adult historical controls. Exposure to artemether and lumefantrine was significantly lower and dihydroartemisinin exposure was unchanged in subjects receiving nevirapine-based ART, compared with controls. Nevirapine exposure was unchanged before and after artemether-lumefantrine administration.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26392500      PMCID： PMC4649208          DOI： 10.1128/AAC.01153-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

Authors:  Naser L Rezk; Richard R Tidwell; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

2.  Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

Authors:  T Kredo; K Mauff; J S Van der Walt; L Wiesner; G Maartens; K Cohen; P Smith; K I Barnes
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

3.  Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria.

Authors:  F Ezzet; M van Vugt; F Nosten; S Looareesuwan; N J White
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

Authors:  D A Erickson; G Mather; W F Trager; R H Levy; J J Keirns
Journal:  Drug Metab Dispos       Date:  1999-12       Impact factor: 3.922

5.  Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.

Authors:  L L von Moltke; D J Greenblatt; B W Granda; G M Giancarlo; S X Duan; J P Daily; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  2001-01       Impact factor: 3.126

6.  How much fat is necessary to optimize lumefantrine oral bioavailability?

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegårdh; Anna Annerberg; Am Kham; Al Brockman; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Trop Med Int Health       Date:  2007-02       Impact factor: 2.622

7.  Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria.

Authors:  Ric N Price; Anne-Catrin Uhlemann; Michele van Vugt; Al Brockman; Robert Hutagalung; Shalini Nair; Denae Nash; Pratap Singhasivanon; Tim J C Anderson; Sanjeev Krishna; Nicholas J White; François Nosten
Journal:  Clin Infect Dis       Date:  2006-04-26       Impact factor: 9.079

8.  Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.

Authors:  Liusheng Huang; Sunil Parikh; Philip J Rosenthal; Patricia Lizak; Florence Marzan; Grant Dorsey; Diane Havlir; Francesca T Aweeka
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

9.  Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.

Authors:  Liusheng Huang; Anura L Jayewardene; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  J Pharm Biomed Anal       Date:  2009-07-07       Impact factor: 3.935

Review 10.  Clinical pharmacology of artemisinin-based combination therapies.

Authors:  Polina I German; Francesca T Aweeka
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
View more
  8 in total

1.  Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?

Authors:  Sa'ad T Abdullahi; Adeniyi Olagunju; Julius O Soyinka; Rahman A Bolarinwa; Olusola J Olarewaju; Moji T Bakare-Odunola; Andrew Owen; Saye Khoo
Journal:  Br J Clin Pharmacol       Date:  2019-01-02       Impact factor: 4.335

2.  Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection.

Authors:  Adebanjo Adegbola; Rana Abutaima; Adeniyi Olagunju; Omotade Ijarotimi; Marco Siccardi; Andrew Owen; Julius Soyinka; Oluseye Bolaji
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.

Authors:  Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

4.  Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.

Authors:  Clifford G Banda; Fraction Dzinjalamala; Mavuto Mukaka; Jane Mallewa; Victor Maiden; Dianne J Terlouw; David G Lalloo; Saye H Khoo; Victor Mwapasa
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

5.  An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.

Authors:  Jose Francis; Karen I Barnes; Lesley Workman; Tamara Kredo; Lasse S Vestergaard; Richard M Hoglund; Pauline Byakika-Kibwika; Mohammed Lamorde; Stephen I Walimbwa; Ifeyinwa Chijioke-Nwauche; Colin J Sutherland; Concepta Merry; Kimberley K Scarsi; Nyagonde Nyagonde; Martha M Lemnge; Saye H Khoo; Ib C Bygbjerg; Sunil Parikh; Francesca T Aweeka; Joel Tarning; Paolo Denti
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes.

Authors:  Sa'ad T Abdullahi; Julius O Soyinka; Adeniyi Olagunju; Rahman A Bolarinwa; Olusola J Olarewaju; Moji T Bakare-Odunola; Markus Winterberg; Joel Tarning; Andrew Owen; Saye Khoo
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

7.  Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.

Authors:  Sunil Parikh; Richard Kajubi; Liusheng Huang; Joshua Ssebuliba; Sylvia Kiconco; Qin Gao; Fangyong Li; Moses Were; Abel Kakuru; Jane Achan; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Infect Dis       Date:  2016-05-03       Impact factor: 9.079

8.  Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Authors:  Liusheng Huang; Vincent Carey; Jane C Lindsey; Florence Marzan; David Gingrich; Bobbie Graham; Linda Barlow-Mosha; Phionah K Ssemambo; Portia Kamthunzi; Sharon Nachman; Sunil Parikh; Francesca T Aweeka
Journal:  PLoS One       Date:  2017-10-24       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.